Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)
Public ClinicalTrials.gov record NCT03676231. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SGM-1019 Administered for 12 Weeks in Subjects With F1-F3 Nonalcoholic Steatohepatitis (NASH)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, pharmacokinetics, and pharmacodynamics of 12 weeks' administration of SGM-1019 in subjects with fibrosis stage 1-3 (F1-F3) NASH.
Study identification
- NCT ID
- NCT03676231
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 9 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 18, 2019 (Actual)
- Primary completion
- May 1, 2019 (Actual)
- Completion
- May 1, 2019 (Actual)
- Last update posted
- Jul 11, 2019
2019
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Second Genome Clinical Site 405 | Chandler | Arizona | 85224 | — |
| Second Genome Clinical Site 406 | Tucson | Arizona | 85712 | — |
| Second Genome Clinical Site 403 | Panorama City | California | 91402 | — |
| Second Genome Clinical Site 409 | Lakewood Rch | Florida | 34211 | — |
| Second Genome Clinical Site 410 | Flowood | Mississippi | 39232 | — |
| Second Genome Clinical Site 404 | Kansas City | Missouri | 64131 | — |
| Second Genome Clinical Site 408 | Fayetteville | North Carolina | 28304 | — |
| Second Genome Clinical Site 407 | Clarksville | Tennessee | 37040 | — |
| Second Genome Clinical Site 402 | Austin | Texas | 78746 | — |
| Second Genome Clinical Site 401 | San Antonio | Texas | 78220 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03676231, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 11, 2019 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03676231 live on ClinicalTrials.gov.